"Herpes Zoster" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)
| Descriptor ID |
D006562
|
| MeSH Number(s) |
C02.256.466.930.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Herpes Zoster".
Below are MeSH descriptors whose meaning is more specific than "Herpes Zoster".
This graph shows the total number of publications written about "Herpes Zoster" by people in this website by year, and whether "Herpes Zoster" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2008 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 0 | 4 |
| 2022 | 2 | 0 | 2 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Herpes Zoster" by people in Profiles.
-
A Rare Case of Varicella Zoster Infection in Hemorrhoids in a Patient With Inflammatory Bowel Disease. Am J Dermatopathol. 2024 Mar 01; 46(3):159-161.
-
Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study. Mov Disord. 2024 Feb; 39(2):438-444.
-
Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States. Vaccine. 2022 11 28; 40(50):7187-7190.
-
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022 04 12; 6(7):2035-2044.
-
Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2022 01 01; 97(1):90-98.
-
Corneal Allograft Rejection Associated With Herpes Zoster Recombinant Adjuvanted Vaccine. Cornea. 2022 Jun 01; 41(6):772-774.
-
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults = 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. Hum Vaccin Immunother. 2021 07 03; 17(7):2050-2057.
-
Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program. BMC Infect Dis. 2021 Jan 11; 21(1):46.
-
Acute zoster plasma contains elevated amyloid, correlating with A?42 and amylin levels, and is amyloidogenic. J Neurovirol. 2020 06; 26(3):422-428.
-
The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Older Adults. Clin Infect Dis. 2019 07 02; 69(2):341-344.